Evaluation of the response to treatment and clinical evolution in patients with burning mouth syndrome

被引:26
作者
Rodriguez-de Rivera-Campillo, Eugenia [1 ,2 ]
Lopez-Lopez, Jose [2 ]
机构
[1] Dermaotologyst Sagrat Cor Hosp, Barcelona, Spain
[2] Univ Barcelona, Sch Dent, E-08007 Barcelona, Spain
来源
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL | 2013年 / 18卷 / 03期
关键词
Burning mouth syndrome; stomatodynia; oral pain; clonazepam; PLACEBO-CONTROLLED TRIAL; SALIVARY FLOW-RATE; ALPHA-LIPOIC ACID; DOUBLE-BLIND; STOMATODYNIA; CLONAZEPAM; REFLEX;
D O I
10.4317/medoral.18142
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: the aim of this study is to investigate the clinical evolution, the spontaneous remission of the symptomatology and the response to different treatments in a group of burning mouth syndrome patients. Study Design: the sample was formed by a group of patients that were visited in the Unit of Oral Medicine of the Dentistry Clinic of the University of Barcelona, from the year 2000 to 2011. After revising the clinical records of all the patients that had been under control for a period of time of 18 months or longer, they were contacted by telephone. In the telephone interview, they were questioned about the symptomatology evolution and the response to the treatments received, noting down the data in a questionnaire previously performed. Results: the average duration of the symptoms was 6.5 years (+/-2.5 years). The most frequent treatments were: chlorhexidine mouthrinses, oral benzodiazepines, topical clonazepam, antiinflamatory drugs, antidepressants, antifungicals, vitamins, psycotherapy, salivary substitutes and topical corticoids. The specialists that were consulted with a higher frequency were: dermatologists (30%), othorrynolaringologists (10%) and psychiatrists (3%). In 41 patients the oral symptoms did not improve, 35 reported partial improvements, 12 patients worsened, and only in 3 patients the symptoms remitted. Conclusions: In three of the 91 patients studied the symptoms remitted spontaneously within the five years of treatment. Only 42% of the study population had improved the symptomatology significantly, and this improvement would reach 60% if clonazepam were associated to psychotherapy.
引用
收藏
页码:E403 / E410
页数:8
相关论文
共 27 条
[1]  
Amos K, 2011, J OROFAC PAIN, V25, P125
[2]   Comparison of treatment modalities in burning mouth syndrome [J].
Barker, K. E. ;
Batstone, M. D. ;
Savage, N. W. .
AUSTRALIAN DENTAL JOURNAL, 2009, 54 (04) :300-305
[3]   Burning mouth syndrome (BMS): sialometric and sialochemical analysis and salivary protein profile [J].
Bezerra de Moura, Sergio Adriane ;
Andrade de Sousa, Jacira Maria ;
Lima, Dilma Ferreira ;
do Monte Negreiros, Andre Newton ;
Silva, Fabio de Vasconcelos ;
da Costa, Lino Joao .
GERODONTOLOGY, 2007, 24 (03) :173-176
[4]   Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial [J].
Cavalcanti, Desiree Rosa ;
Xavier da Silveira, Fernando Ricardo .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2009, 38 (03) :254-261
[5]  
Danhauer SC, 2002, J OROFAC PAIN, V16, P305
[6]  
El-Etr M, 2009, J OROFAC PAIN, V23, P216
[7]   Oral sensorial complaints, salivary flow rate and mucosal lesions in the institutionalized elderly [J].
Glazar, I. ;
Urek, M. M. ;
Brumini, G. ;
Pezelj-Ribaric, S. .
JOURNAL OF ORAL REHABILITATION, 2010, 37 (02) :93-99
[8]   Topical clonazepam in stomatodynia: a randomised placebo-controlled study [J].
Gremeau-Richard, C ;
Woda, A ;
Navez, ML ;
Attal, N ;
Bouhassira, D ;
Gagnieu, MC ;
Laluque, JF ;
Picard, P ;
Pionchon, P ;
Tubert, S .
PAIN, 2004, 108 (1-2) :51-57
[9]  
GRUSHKA M, 1991, Dental Clinics of North America, V35, P171
[10]   Role of the dopaminergic system in chronic pain -: a fluorodopa-PET study [J].
Jääskeläinen, SK ;
Rinne, JO ;
Forssell, H ;
Tenovuo, O ;
Kaasinen, V ;
Sonninen, P ;
Bergman, J .
PAIN, 2001, 90 (03) :257-260